Actively Recruiting
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Led by ModernaTX, Inc. · Updated on 2026-05-11
166
Participants Needed
10
Research Sites
350 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
CONDITIONS
Official Title
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults with relapsed or refractory multiple myeloma who have prior exposure to a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody
- Measurable disease defined by at least one of the following: serum M-protein 60.5 grams/deciliter, urine M-protein 60200 milligrams per 24 hours, involved free light chain 60100 mg/liter with abnormal free light chain ratio, plasmacytoma with diameter 62 centimeters, or bone marrow plasma cells greater than 30%
You will not qualify if you...
- Known central nervous system (CNS) myeloma or clinical signs and symptoms of CNS involvement
- Active plasma cell leukemia with peripheral blood plasma cells 20% or greater
- Radiotherapy or cytotoxic chemotherapy within 2 weeks prior to baseline except limited palliative radiotherapy after sponsor discussion
- Antibody-based immunotherapy within 21 days prior to baseline
- Proteasome inhibitor therapy or immunomodulatory agent within 14 days prior to baseline
- Autologous hematopoietic cell transplant within 100 days prior to baseline
- Allogeneic hematopoietic cell transplant within 180 days prior to baseline
- Genetically modified adoptive cellular therapy within 12 weeks prior to baseline
- Corticosteroid therapy with prednisone equivalent dose 140 mg or more within 14 days prior to baseline
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
University of Alabama at Birmingham Hospital
Birmingham, Alabama, United States, 35233
Actively Recruiting
2
UCSF
San Francisco, California, United States, 94143
Not Yet Recruiting
3
Emory University Hospital
Atlanta, Georgia, United States, 30322
Actively Recruiting
4
Mass General Brigham
Boston, Massachusetts, United States, 02114
Not Yet Recruiting
5
Tisch Cancer Institute at Mount Sinai
New York, New York, United States, 10029
Actively Recruiting
6
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Not Yet Recruiting
7
Atrium Health Levine Cancer Institute
Charlotte, North Carolina, United States, 28204
Not Yet Recruiting
8
Penn Medicine
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
9
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Actively Recruiting
10
The Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
Research Team
M
Moderna WeCare Team
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here